Classic inflammatory diseases of the skeletal muscle such as polymyositis and dermatomyositis often lead to rapid weakening of the arm and leg muscles. Inflammation in the muscle is caused primarily by immune cells and antibodies. Most patients respond well to standard immunosuppressive therapy. In sporadic inclusion body myositis (sIBM), similar pathomechanisms play a role, including cytotoxic T-lymphocytes, which attack and damage muscle fibers. At the same time, sIBM is characterized by an accumulation of aberrant molecules, particularly β-amyloid, which play a role in neurodegenerative diseases. This degeneration with formation of inclusion bodies and vacuoles may be the cause of the slow yet relentlessly progressive damage to the skeletal muscle and the lack of treatment efficacy of standard immunosuppression. Recent reports demonstrate that there is a specific interrelationship between inflammation with generation of mediators such as interleukin (IL)-1β and the amyloid-associated degeneration. The molecular mechanisms discussed here are important for the future design of better treatment strategies for chronic muscle inflammation. Furthermore, these mechanisms can contribute to a better understanding of the pathogenesis of neurodegenerative diseases.